Stocks Health care CVKD

NASDAQ · Health care

Cadrenal Therapeutics, Inc. (CVKD)

It posted a net loss of $11.5M. In fiscal 2025 capital spending exceeded operating cash flow by $12.6M. At June 30, 2026 it held $2.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Cadrenal Therapeutics, Inc. does

Cadrenal Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CVKD.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Dividends

Cadrenal Therapeutics, Inc. declared $16.50 per share in fiscal 2025. At the current price that is a yield of 1,434.78%.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Cadrenal Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 3, 2026
   Employee stock plan registration S-8
2. August 31, 2026
   Investor disclosure 8-K
3. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$1.14 versus -$1.87.
4. August 13, 2026
   Quarterly results 8-K
5. August 3, 2026
   Additional proxy material DEFA14A
6. August 3, 2026
   Annual report to shareholders ARS
7. August 3, 2026
   Proxy statement DEF 14A
8. July 23, 2026
   Preliminary proxy statement PRE 14A
9. July 21, 2026
   Investor disclosure 8-K
10. July 20, 2026
    Securities offering prospectus 424B3

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 1, 2026. Insider transactions on SEC

Insider trades

What the people running Cadrenal Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $22.4K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CVKD

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 98,589 shares in total, about $113.4K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CVKD

What does Cadrenal Therapeutics, Inc. do?

Cadrenal Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CVKD.

Is Cadrenal Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $11.5M.

When did Cadrenal Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from September 3, 2026.

Similar companies

Compare CVKD with

Compare CVKD with any company

Follow CVKD

Get an email when Cadrenal Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CVKD: get an email when it files

Where the numbers come from

Financial figures are the values Cadrenal Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.